Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update

References

• World Health Organization. World malaria report 2022. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022. Accessed April 9, 2023.
   Google Scholar
• Manescu P, Shaw MJ, Elmi M, et al. Expert-level automated malaria diagnosis on routine blood films with deep neural networks. Am J Hematol. 2020;95(8):883–891. doi:10.1002/AJH.25827
   PubMed Web of Science ®Google Scholar
• Laurens MB. RTS,S/AS01 vaccine (MosquirixTM): an overview. Hum Vaccin Immunother. 2020;16(3):480–489. doi:10.1080/21645515.2019.1669415
   PubMed Web of Science ®Google Scholar
• Elimination T malERA RCP on T for M. malERA: an updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLOS Med. 2017;14(11):e1002455. doi:10.1371/JOURNAL.PMED.1002455
   PubMed Web of Science ®Google Scholar
• Peterson I, Kapito-Tembo A, Bauleni A, et al. Overdiagnosis of malaria illness in an endemic setting: a facility-based surveillance study in Malawi. Am J Trop Med Hyg. 2021;104(6):2123–2130. doi:10.4269/ajtmh.20-1209
   PubMed Web of Science ®Google Scholar
• Scally SW, Murugan R, Bosch A, et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J Exp Med. 2018;215(1):63–75. doi:10.1084/JEM.20170869
   PubMed Web of Science ®Google Scholar
• Cha S-J, Kim M-S, Na CH, Jacobs-Lorena M. Plasmodium sporozoite phospholipid scramblase interacts with mammalian carbamoyl-phosphate synthetase 1 to infect hepatocytes. Nat Commun. 2021;12(1). doi:10.1038/S41467-021-27109-7
   Web of Science ®Google Scholar
• Langowski MD, Khan FA, Savransky S, et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. Npj Vaccines. 2022;7(1):13. doi:10.1038/S41541-022-00430-Y
   PubMed Web of Science ®Google Scholar
• Uyar Y, Akşit A, Karaca S, Ceylan ŞS, Yürük M. 37 NANP ve 4 NVDP Epitoplu Plasmodium falciparum Rekombinant Circumsporozoite Proteinin Ekspresyonu ve Moleküler Karakterizasyonu [Production and molecular characterization of Plasmodium falciparum recombinant circumsporozoite protein with 37 NANP and 4 NVDP epitopes]. Mikrobiyol Bul. 2017;51(1):41–51. Turkish. doi:10.5578/mb.46549
   PubMedGoogle Scholar
• RTS, S Clinical Trials Partnership. A Phase 3 trial of RTS,S/AS01 malaria vaccine in African Infants. N Engl J Med. 2012;367(24):2284–2295. doi:10.1056/NEJMOA1208394
   PubMed Web of Science ®Google Scholar
• First Results of Phase. A Phase 3 trial of RTS,S/AS01 malaria vaccine in African Children. N Engl J Med. 2011;365(20):1863–1875. doi:10.1056/nejmoa1102287
   PubMed Web of Science ®Google Scholar
• Malaria: phase 3 trial results for vaccine RTS,S/AS01. Available from: https://www.who.int/news-room/questions-and-answers/item/phase-3-trial-results-for-malaria-vaccine-rtss-as01. Accessed November 21, 2022.
   Google Scholar
• Zhang YL, Pan WQ. The world’s first malaria vaccine: hope and challenge. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022;33(6):560–562. doi:10.16250/j.32.1374.2021283
   PubMedGoogle Scholar
• Arora N, Anbalagan L, Pannu AK. Towards eradication of malaria: is the WHO’s RTS,S/AS01 vaccination effective enough? Risk Manag Healthc Policy. 2021;14:1033–1039. doi:10.2147/RMHP.S219294
   PubMed Web of Science ®Google Scholar
• Kurtovic L, Wetzel D, Reiling L, et al. Novel virus-like particle vaccine encoding the circumsporozoite protein of plasmodium falciparum is immunogenic and induces functional antibody responses in mice. Front Immunol. 2021;12. doi:10.3389/FIMMU.2021.641421
   Web of Science ®Google Scholar
• McCann RS, Kabaghe AN, Moraga P, et al. The effect of community-driven larval source management and house improvement on malaria transmission when added to the standard malaria control strategies in Malawi: a cluster-randomized controlled trial. Malar J. 2021;20(1). doi:10.1186/s12936-021-03769-0
   Web of Science ®Google Scholar
• Vareta J, Buchwald AG, Barrall A, et al. Submicroscopic malaria infection is not associated with fever in cross-sectional studies in Malawi. Malar J. 2020;19(1). doi:10.1186/s12936-020-03296-4
   PubMed Web of Science ®Google Scholar
• Oseno B, Marura F, Ogwang R, et al. Characterization of Anopheles gambiae D7 salivary proteins as markers of human–mosquito bite contact. Parasit Vectors. 2022;15(1). doi:10.1186/s13071-021-05130-5
   PubMed Web of Science ®Google Scholar
• Wahl I, Wardemann H. How to induce protective humoral immunity against Plasmodium falciparum circumsporozoite protein. J Exp Med. 2022;219(2). doi:10.1084/jem.20201313
   Web of Science ®Google Scholar
• Reiling L, Boyle MJ, White MT, et al. Targets of complement-fixing antibodies in protective immunity against malaria in children. Nat Commun. 2019;10(1). doi:10.1038/s41467-019-08528-z
   PubMedGoogle Scholar
• Leitner WW, Haraway M, Pierson T, Bergmann-Leitner ES. Role of opsonophagocytosis in immune protection against malaria. Vaccines. 2020;8(2):264. doi:10.3390/vaccines8020264
   Web of Science ®Google Scholar
• Langowski MD, Khan FA, Bitzer AA, et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc Natl Acad Sci U S A. 2020;117(6):3114–3122. doi:10.1073/pnas.1911792117
   PubMed Web of Science ®Google Scholar
• Kisalu NK, Idris AH, Weidle C, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408–416. doi:10.1038/nm.4512
   PubMed Web of Science ®Google Scholar
• Jelínková L, Jhun H, Eaton A, Petrovsky N, Zavala F, Chackerian B. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. Npj Vaccines. 2021;6(1). doi:10.1038/S41541-020-00274-4
   PubMed Web of Science ®Google Scholar
• Francica JR, Shi W, Chuang GY, et al. Design of alphavirus virus-like particles presenting circumsporozoite junctional epitopes that elicit protection against malaria. Vaccines. 2021;9(3):272. doi:10.3390/VACCINES9030272
   Web of Science ®Google Scholar
• Herrera R, Anderson C, Kumar K, et al. Reversible conformational change in the plasmodium falciparum circumsporozoite protein masks Its adhesion domains. Infect Immun. 2015;83(10):3771–3780. doi:10.1128/IAI.02676-14
   PubMed Web of Science ®Google Scholar
• PATH’s malaria vaccine initiative. Available from: https://www.malariavaccine.org/files/content/page/files/RTSS.FAQs_FINAL.pdf. Accessed February 4, 2023.
   Google Scholar
• de Almeida MEM, Alves KCS, de Vasconcelos MGS, et al. Bacillus subtilis spores as delivery system for nasal Plasmodium falciparum circumsporozoite surface protein immunization in a murine model. Sci Rep. 2022;12(1):1–8. doi:10.1038/s41598-022-05344-2
   PubMed Web of Science ®Google Scholar
• Wang LT, Hurlburt NK, Schön A, et al. The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria. Cell Rep. 2022;38(7):110367. doi:10.1016/j.celrep.2022.110367
   PubMed Web of Science ®Google Scholar
• White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10(1):297. doi:10.1186/1475-2875-10-297
   PubMed Web of Science ®Google Scholar
• Calvo-Calle JM, Mitchell R, Altszuler R, Othoro C, Nardin E. Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein. Npj Vaccines. 2021;6(1):1–8. doi:10.1038/s41541-020-00272-6
   PubMed Web of Science ®Google Scholar
• McNamara HA, Idris AH, Sutton HJ, et al. Antibody feedback limits the expansion of B cell responses to malaria vaccination but drives diversification of the humoral response. Cell Host Microbe. 2020;28(4):572–585.e7. doi:10.1016/j.chom.2020.07.001
   PubMed Web of Science ®Google Scholar
• McCall MBB, Kremsner PG, Mordmüller B. Correlating efficacy and immunogenicity in malaria vaccine trials. Semin Immunol. 2018;39:52–64. doi:10.1016/j.smim.2018.08.002
   PubMed Web of Science ®Google Scholar
• Jensen AR, Adams Y, Hviid L. Cerebral Plasmodium falciparum malaria: the role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunol Rev. 2020;293(1):230–252. doi:10.1111/imr.12807
   PubMed Web of Science ®Google Scholar
• Suscovich TJ, Fallon JK, Das J, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020;12(553). doi:10.1126/SCITRANSLMED.ABB4757
   PubMed Web of Science ®Google Scholar
• Feng G, Wines BD, Kurtovic L, et al. Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites. Nat Commun. 2021;12(1). doi:10.1038/S41467-021-21998-4
   Web of Science ®Google Scholar
• Kurtovic L, Atre T, Feng G, et al. Multifunctional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase 1/2a trial. J Infect Dis. 2021;224(7):1128–1138. doi:10.1093/INFDIS/JIAA144
   PubMed Web of Science ®Google Scholar
• Garcia-Senosiain A, Kana IH, Singh S, et al. Neutrophils dominate in opsonic phagocytosis of P. falciparum blood-stage merozoites and protect against febrile malaria. Commun Biol. 2021;4(1). doi:10.1038/S42003-021-02511-5
   PubMed Web of Science ®Google Scholar
• Opi DH, Kurtovic L, Chan JA, Horton JL, Feng G, Beeson JG. Multi-functional antibody profiling for malaria vaccine development and evaluation. Expert Rev Vaccines. 2021;20(10):1257–1272. doi:10.1080/14760584.2021.1981864
   PubMed Web of Science ®Google Scholar
• Mugo RM, Mwai K, Mwacharo J, et al. Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children. Malar J. 2021;20(1):1–8. doi:10.1186/s12936-021-03961-2
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359(24):2521. doi:10.1056/NEJMOA0807381
   PubMed Web of Science ®Google Scholar
• Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368(12):1111–1120. doi:10.1056/NEJMOA1207564/SUPPL_FILE/NEJMOA1207564_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Tan J, Cho H, Pholcharee T, et al. Functional human IgA targets a conserved site on malaria sporozoites. Sci Transl Med. 2021;13(599). doi:10.1126/scitranslmed.abg2344
   Web of Science ®Google Scholar
• Gaudinski MR, Berkowitz NM, Idris AH, et al. A monoclonal antibody for malaria prevention. N Engl J Med. 2021;385(9):803–814. doi:10.1056/NEJMOA2034031
   PubMed Web of Science ®Google Scholar
• Kurtovic L, Drew DR, Dent AE, Kazura JW, Beeson JG. Antibody targets and properties for complement-fixation against the circumsporozoite protein in malaria immunity. Front Immunol. 2021;12:1–12. doi:10.3389/fimmu.2021.775659
   Web of Science ®Google Scholar
• Bergmann-Leitner ES, Scheiblhofer S, Weiss R, et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol. 2005;17(3):245–255. doi:10.1093/INTIMM/DXH205
   PubMed Web of Science ®Google Scholar
• Schofield L, Uadia P. Lack of Ir gene control in the immune response to malaria. I. A thymus-independent antibody response to the repetitive surface protein of sporozoites. J Immunol. 1990;144(7):2781–2788. doi:10.4049/jimmunol.144.7.2781
   PubMed Web of Science ®Google Scholar
• Goundis D, Reid KBM. Properdin, the terminal complement components, thrombospondin and the circumsporozoite protein of malaria parasites contain similar sequence motifs. Nature. 1988;335(6185):82–85. doi:10.1038/335082A0
   PubMed Web of Science ®Google Scholar
• Meraldi V, Audran R, Romero JF, et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine. 2003;21(19–20):2485–2491. doi:10.1016/S0264-410X(03)00093-8
   PubMed Web of Science ®Google Scholar
• Pholcharee T, Oyen D, Flores-Garcia Y, et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat Commun. 2021;12(1). doi:10.1038/s41467-021-21221-4
   PubMed Web of Science ®Google Scholar
• Thai E, Costa G, Weyrich A, et al. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity. J Exp Med. 2020;217(11). doi:10.1084/JEM.20200061
   PubMed Web of Science ®Google Scholar
• Flores-Garcia Y, Wang LT, Park M, et al. The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo. PLoS Pathog. 2021;17(11):1–15. doi:10.1371/journal.ppat.1010042
   Web of Science ®Google Scholar
• Chaudhury S, MacGill RS, Early AM, et al. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine. Vaccine. 2021;39(6):968–975. doi:10.1016/J.VACCINE.2020.12.055
   PubMed Web of Science ®Google Scholar
• Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2Pt A):171–182. doi:10.1016/J.MOLIMM.2015.03.255
   PubMed Web of Science ®Google Scholar
• Ubillos I, Ayestaran A, Nhabomba AJ, et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Med. 2018;16(1). doi:10.1186/S12916-018-1186-4
   PubMedGoogle Scholar
• Kurtovic L, Behet MC, Feng G, et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med. 2018;16(1). doi:10.1186/S12916-018-1054-2
   PubMedGoogle Scholar
• Stanisic DI, Fowkes FJI, Koinari M, et al. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun. 2015;83(2):646–660. doi:10.1128/IAI.02398-14
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, De Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–1263. doi:10.1126/SCIENCE.1248943
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–1052. doi:10.1182/BLOOD-2002-06-1761
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJM, Wiegman LJJM, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362–371. doi:10.4049/JIMMUNOL.177.1.362
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Ockenhouse CF, Regules JA, et al. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Malar J. 2016;15(1):1–12. doi:10.1186/S12936-016-1348-9/FIGURES/8
   PubMedGoogle Scholar
• Kester KE, McKinney DA, Tornieporth N, et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine. 2007;25(29):5359–5366. doi:10.1016/J.VACCINE.2007.05.005
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337–346. doi:10.1086/600120
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364(9443):1411–1420. doi:10.1016/S0140-6736(04)17223-1
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Fernandes JF, et al. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLOS Med. 2014;11(7):e1001685. doi:10.1371/JOURNAL.PMED.1001685
   PubMed Web of Science ®Google Scholar
• Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984;132(2):909–913. doi:10.4049/jimmunol.132.2.909
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Wery M, Sharma P. A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect Immun. 1995;63(11). doi:10.1128/IAI.63.11.4375-4381.1995
   PubMed Web of Science ®Google Scholar
• Rathore D, Nagarkatti R, Jani D, et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem. 2005;280(21):20524–20529. doi:10.1074/JBC.M414254200
   PubMed Web of Science ®Google Scholar
• Oyen D, Torres JL, Wille-Reece U, et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A. 2017;114(48):E10438–E10445. doi:10.1073/PNAS.1715812114
   PubMed Web of Science ®Google Scholar
• Beeson JG, Kurtovic L, Dobaño C, et al. Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med. 2019;11(474). doi:10.1126/SCITRANSLMED.AAU1458
   PubMed Web of Science ®Google Scholar
• Kurtovic L, Agius PA, Feng G, et al. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. BMC Med. 2019;17(1). doi:10.1186/S12916-019-1277-X
   PubMedGoogle Scholar
• Kester KE, McKinney DA, Tornieporth N, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 2001;183(4):640–647. doi:10.1086/318534
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, et al.; RTS,S Malaria Vaccine Evaluation Group. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med. 1997;336(2):86–91. doi:10.1056/NEJM199701093360202
   PubMed Web of Science ®Google Scholar
• Illingworth J, Butler NS, Roetynck S, et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol. 2013;190(3):1038–1047. doi:10.4049/JIMMUNOL.1202438
   PubMed Web of Science ®Google Scholar
• Chandramohan D, Zongo I, Sagara I, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385(11):1005–1017. doi:10.1056/NEJMOA2026330
   PubMed Web of Science ®Google Scholar
• Nielsen CM, Vekemans J, Lievens M, Kester KE, Regules JA, Ockenhouse CF. RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. Vaccine. 2018;36(12):1637–1642. doi:10.1016/J.VACCINE.2018.01.069
   PubMed Web of Science ®Google Scholar
• Portugal S, Pierce SK, Crompton PD. Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J Immunol. 2013;190(7):3039–3046. doi:10.4049/JIMMUNOL.1203067
   PubMed Web of Science ®Google Scholar
• Scherf A, Lopez-Rubio JJ, Riviere L. Antigenic variation in Plasmodium falciparum. Annu Rev Microbiol. 2008;62:445–470. doi:10.1146/ANNUREV.MICRO.61.080706.093134
   PubMed Web of Science ®Google Scholar
• Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming “vaccine resistant malaria”. Parasite Immunol. 2009;31(9):560–573. doi:10.1111/J.1365-3024.2009.01138.X
   PubMed Web of Science ®Google Scholar
• Urban BC, Hien TT, Day NP, et al. Fatal Plasmodium falciparum malaria causes specific patterns of splenic architectural disorganization. Infect Immun. 2005;73(4):1986–1994. doi:10.1128/IAI.73.4.1986-1994.2005
   PubMed Web of Science ®Google Scholar
• Ibison F, Olotu A, Muema DM, et al. Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya. PLoS One. 2012;7(12):e52939. doi:10.1371/JOURNAL.PONE.0052939
   PubMed Web of Science ®Google Scholar
• Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267–285. doi:10.1146/ANNUREV.IMMUNOL.021908.132607
   PubMed Web of Science ®Google Scholar
• Weiss GE, Crompton PD, Li S, et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol. 2009;183(3):2176–2182. doi:10.4049/JIMMUNOL.0901297
   PubMed Web of Science ®Google Scholar
• Asito AS, Moormann AM, Kiprotich C, Ng’ang’A ZW, Ploutz-Snyder R, Rochford R. Alterations on peripheral B cell subsets following an acute uncomplicated clinical malaria infection in children. Malar J. 2008;7. doi:10.1186/1475-2875-7-238
   PubMed Web of Science ®Google Scholar
• Butler NS, Moebius J, Pewe LL, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol. 2011;13(2):188–195. doi:10.1038/ni.2180
   PubMed Web of Science ®Google Scholar
• Donati D, Mok B, Chêne A, et al. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol. 2006;177(5):3035–3044. doi:10.4049/JIMMUNOL.177.5.3035
   PubMed Web of Science ®Google Scholar
• Nduati E, Gwela A, Karanja H, et al. The plasma concentration of the B cell activating factor is increased in children with acute malaria. J Infect Dis. 2011;204(6):962–970. doi:10.1093/INFDIS/JIR438
   PubMed Web of Science ®Google Scholar
• Traore B, Koné Y, Doumbo S, et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine. 2009;27(52):7299–7303. doi:10.1016/J.VACCINE.2009.08.023
   PubMed Web of Science ®Google Scholar
• Daniel-Ribeiro CT, Zanini G. Autoimmunity and malaria: what are they doing together? Acta Trop. 2000;76(3):205–221. doi:10.1016/S0001-706X(00)00099-1
   PubMed Web of Science ®Google Scholar